Preemptive therapy versus universal prophylaxis: Time for reconciliation?

被引：2
|
作者：
Kampouri, Eleftheria [1 ]
Manuel, Oriol [2 ,3 ,4 ,5 ]
机构：
[1] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[2] Lausanne Univ Hosp, Infect Dis Serv & Transplantat Ctr, Lausanne, Switzerland
[3] Univ Lausanne, Lausanne, Switzerland
[4] Lausanne Univ Hosp, Infect Dis Serv & Transplantat Ctr, BH10-549,Bugnon 46, CH-1011 Lausanne, Switzerland
[5] Univ Lausanne, BH10-549,Bugnon 46, CH-1011 Lausanne, Switzerland
来源：
TRANSPLANT INFECTIOUS DISEASE | 2023年 / 25卷 / 02期
关键词：
ONSET CYTOMEGALOVIRUS DISEASE; LIVER-TRANSPLANT RECIPIENTS; ANTIVIRAL PROPHYLAXIS;
D O I：
10.1111/tid.14014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CMV VALGANCICLOVIR PROPHYLAXIS VERSUS PREEMPTIVE THERAPY AFTER RENAL TRANSPLANTATION: ONE YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL
    Witzke, O.
    Nitschke, M.
    Bartels, M.
    Ott, U.
    Hauser, I. A.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 12 - 12
  • [32] CMV Valganciclovir Prophylaxis Versus Preemptive Therapy after Renal Transplantation: Three Year Results of a Randomized Clinical Trial
    Hauser, I. A.
    Wolf, G.
    Wolters, H.
    Nitschke, M.
    Vonend, O.
    Witzke, O.
    TRANSPLANTATION, 2012, 94 (10) : 83 - 83
  • [33] Surveillance For Reactivation of Toxoplasma Gondii using Polymerase Chain Reaction Assay and preemptive Therapy Avoids Universal Prophylaxis and Prevents Symptomatic Infection
    Amer, Mariam
    Richardson, Deborah S.
    Dalley, Christopher
    Hill, Kate S.
    Main, Sara
    Snow, Helen
    Creighton, Amy
    Mckeag, Nikki
    Newman, Joan
    Jarvis, Linda
    Holtby, Sarah
    Orchard, Kim H.
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 461 - 462
  • [34] Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients
    Vymetalova, Jevgenija
    Kubanek, Milos
    Gazdic, Tomas
    Vrbska, Jana
    Malek, Ivan
    Kautzner, Josef
    COR ET VASA, 2012, 54 (01) : E16 - E21
  • [35] CMV Valganciclovir Prophylaxis Versus Preemptive Therapy after Renal Transplantation: Two Year Results of a Randomized Clinical Trial.
    Witzke, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 210 - 210
  • [36] Origen and universal reconciliation
    Babolin, A
    RIVISTA DI FILOSOFIA NEO-SCOLASTICA, 1999, 91 (03) : 504 - 504
  • [37] Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation
    Tan, Carrie A.
    Palen, Lauren
    Su, Yiqi
    Li, Yuxuan
    Gennarelli, Renee L.
    Perales, Miguel-Angel
    Cohen, Nina
    Papanicolaou, Genovefa A.
    Shah, Gunjan L.
    Seo, Susan K.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (08): : 792e1 - 792e12
  • [38] Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy
    Carualho, Fabiana Rabe
    Juliboni Cosendey, Rachel Ingrid
    Souza, Cintia Fernandes
    Medeiros, Thalia
    Menezes, Paulo Alexandre
    Silva, Andrea Alice
    Almeida, Jorge Reis
    Lugon, Jocemir Ronaldo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2017, 21 (01): : 51 - 56
  • [39] Use of Valgancyclovir in the prophylaxis; Preemptive and directed therapy following solid organ transplantation
    Bonatti, H
    Cakar, F
    Hoefer, D
    Boesmueller, C
    Ruttmann, E
    Antretter, H
    Mueller, L
    Steurer, W
    Hengster, P
    Geltner, C
    Larcher, C
    Laufer, G
    Margreiter, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 338 - 338
  • [40] Prophylaxis, empirical, preemptive therapy in presumed aspergillosis in hematolological patients: which strategy?
    Maschmeyer, G.
    MYCOSES, 2009, 52 : 5 - 6
12345